ELVIS NGYIA: Open Payments
NPI 1316245558 · GRAND PRAIRIE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,362 in 86 payments from 9 companies in 2025. Trend: 2023 $27,505 · 2024 $990 · 2025 $1,362
Food & beverage: $1,356Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $319 |
| Janssen Pharmaceuticals, Inc | 13 | $283 |
| ABBVIE INC. | 25 | $214 |
| Supernus Pharmaceuticals, Inc. | 21 | $141 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $119 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| Biogen, Inc. | 2 | $35 |
Products named: ARISTADA, VRAYLAR, INVEGA SUSTENNA, Qelbree, REXULTI, CAPLYTA, SPRAVATO, LYBALVI.
Industry payments across TX — which companies pay providers there.
